Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus

Scott A Rush1, Gurpreet Brar2, Ching-Lin Hsieh1

  • 1Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Cell Reports
|September 21, 2022
PubMed

Insights

Human metapneumovirus (hMPV) infection elicits a diverse antibody response in older adults. Researchers identified potent neutralizing antibodies targeting the hMPV fusion (F) protein, crucial for vaccine development.

Area of Science:

  • Virology
  • Immunology
  • Structural Biology

Background:

  • Human metapneumovirus (hMPV) causes significant respiratory illness, particularly in vulnerable populations.
  • Currently, no vaccines or treatments exist for hMPV infections.
  • The viral fusion (F) glycoprotein is a key target for neutralizing antibodies, but the natural immune response is poorly understood.

Purpose of the Study:

  • To investigate the humoral immune response to hMPV infection in older adults.
  • To characterize the antibody repertoire targeting the hMPV F protein.
  • To inform the development of hMPV vaccines and therapeutics.

Main Methods:

  • Analysis of memory B cell antibody sequences from older adults post-hMPV infection.
  • Production and characterization of monoclonal antibodies against the hMPV F protein.
  • Cryo-electron microscopy (Cryo-EM) to determine structural details of antibody-F protein interactions.

Main Results:

  • A highly polyclonal antibody response involving 563 distinct clonotypes was observed.
  • 136 monoclonal antibodies demonstrated broad recognition of the F protein surface.
  • Potently neutralizing antibodies were identified targeting multiple antigenic sites, including two novel non-canonical sites.

Conclusions:

  • Natural hMPV infection in older adults generates a broad and potent neutralizing antibody response.
  • Structural insights reveal key vulnerable sites on the hMPV F protein.
  • These findings provide a foundation for designing effective hMPV vaccines.